IRIDEX (NASDAQ:IRIX) Major Shareholder Shih-Yao David Lin Buys 14,202 Shares of Company Stock

IRIDEX Corporation (NASDAQ:IRIX) major shareholder Shih-Yao David Lin acquired 14,202 shares of the stock in a transaction on Friday, December 19th. The stock was bought at an average price of $0.97 per share, with a total value of $13,775.94. Following the transaction, the insider directly owned 938,929 shares in the company, valued at approximately $910,761.13. This represents a 1.54% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Large shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

IRIDEX Trading Up 29.4%

Shares of NASDAQ IRIX opened at $0.88 on Thursday. IRIDEX Corporation has a 1-year low of $0.61 and a 1-year high of $1.65. The company has a 50-day moving average of $0.73 and a two-hundred day moving average of $0.95. The company has a market cap of $15.46 million, a PE ratio of -4.40 and a beta of 0.67.

IRIDEX (NASDAQ:IRIX) last released its quarterly earnings results on Tuesday, August 18th. The medical equipment provider reported ($0.07) EPS for the quarter, missing the consensus estimate of ($0.01) by ($0.06). The firm had revenue of $12.57 million for the quarter, compared to analyst estimates of $13.59 million. As a group, equities research analysts forecast that IRIDEX Corporation will post -0.12 earnings per share for the current year.

Institutional Trading of IRIDEX

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Weber Capital Management LLC ADV acquired a new position in IRIDEX during the 2nd quarter valued at about $206,616. United Capital Financial Advisors LLC acquired a new stake in shares of IRIDEX during the 2nd quarter worth approximately $41,000. Diversify Advisory Services LLC bought a new stake in shares of IRIDEX during the second quarter worth approximately $30,000. Diversify Wealth Management LLC bought a new stake in shares of IRIDEX during the first quarter worth approximately $35,000. Finally, Bank of New York Mellon Corp acquired a new position in IRIDEX in the second quarter valued at approximately $29,000. 20.10% of the stock is owned by institutional investors.

Analyst Ratings Changes

Separately, Weiss Ratings upgraded IRIDEX from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, October 2nd. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $3.00.

More IRIDEX News

Here are the key news stories impacting IRIDEX this week:

• Positive Sentiment: SEC disclosures show Lin made dozens of purchases totaling substantial share amounts, including transactions of 50,000 shares at $0.99, 40,114 shares at $1.00 and 80,000 shares at $1.00. The repeated buying and growing ownership stake may be interpreted as a sign of confidence in IRIDEX’s long-term prospects. IRIDEX major shareholder buys 50,000 shares
• Positive Sentiment: The filings also include purchases at prices ranging from approximately $0.84 to $1.52, with several individual transactions valued between roughly $20,000 and $58,000. This broad pattern of buying, rather than a single isolated trade, likely attracted speculative interest in the thinly traded stock. IRIDEX major shareholder acquires stock
• Neutral Sentiment: Investors should note that most purchases occurred weeks or months earlier, from March through June and in prior reporting periods; the disclosures are new, but the buying itself is not. The reports therefore provide sentiment support rather than evidence of a new operating development or immediate improvement in revenue and earnings.
• Neutral Sentiment: Trading in IRIX was temporarily halted under a Limit Up-Limit Down (LULD) pause, indicating that the stock’s rapid move exceeded permitted price bands. This highlights significant volatility and the potential for sharp reversals once trading resumes.

About IRIDEX

IRIDEX Corporation (NASDAQ: IRIX) develops and sells ophthalmic laser systems and related delivery devices used in the treatment of eye diseases. Its products are designed primarily for ophthalmologists treating glaucoma and retinal disorders, including diabetic retinopathy and other conditions affecting the retina.

The company’s portfolio includes laser systems such as the Cyclo G6 glaucoma laser platform and the IQ series of retinal photocoagulation lasers. IRIDEX also offers specialized probes and other delivery devices, including MicroPulse and transscleral cyclophotocoagulation technologies, which are intended to provide targeted treatment while limiting exposure to surrounding tissue.

Founded in 1989 and headquartered in Mountain View, California, IRIDEX serves eye-care professionals through a combination of direct sales and distributor relationships in the United States and international markets.